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Background: The so-called Philadelphia (Ph) chromosome is present in almost all cases with chronic myeloid
leukemia (CML). Around 5-10% of these patients show complex translocations involving other chromosomes in
addition to and/or besides chromosomes 9 and 22. As nowadays most CML cases are treated with Imatinib, variant
rearrangements have in general no specific prognostic significance, though events of therapy resistance remain to
be studied.
Results: Here we report a Ph chromosome positive patient with hematological typical chronic phase CML.
Untypically, an unbalanced complex rearrangement involving chromosomes 16 and 17 leading to a deletion of
16pter and partial trisomy of 17q21 to 17qter, was identified besides a trisomy 8 and an additional Ph
chromosome in a part of malignant cells.
Conclusion: Here a novel and cytogenetically unique case of a Ph chromosome positive CML clinically in chronic
phase is reported, having complex secondary chromosomal aberrations. Thus, CML patients with complex
chromosomal changes are nonetheless treatable by Imatinib.
Background
Chronic myeloid leukemia (CML) is a clonal malignant
disorder of a pluripotent hematopoetic stem cell charac-
terized by the presence of the Philadelphia (Ph) chromo-
some in more than 90% of patients. The Ph chromosome
is a product of the reciprocal translocation t(9;22)(q34;
q11), which transposes the 3’ portion of the ABL onco-
gene from 9q34 to the 5’ portion of the BCR gene on
22q11.2. The crucial pathogenetic consequence of this
translocation is the creation of a chimeric BCR/ABL gene
on the derivative chromosome 22 [1]. The expression of
the BCR/ABL chimeric protein with an increased tyro-
sine kinase activity plays an essential role in the patho-
genesis of CML [2].
The progression of CML from chronic phase (CP) to
blast crisis (BC) is frequently associated with nonrandom
secondary chromosomal aberrations such as +8, i(17q),
+19 and an extra Ph chromosome [3]. Imatinib mesylate
(Glivec, formerly STI571) was designed specifically to
inhibit the tyrosine kinase activity of the BCR/ABL pro-
tein and other tyrosine kinases such as cABL, c-KIT and
PDGF (platelet-derived growth factor receptor). By bind-
ing to an active site of the tyrosine kinase, Glivec
switches off downstream signaling, cells stop proliferating
and apoptosis ensues [4]. Many studies have shown a
high efficiency of Imatinib therapy to achieve a complete
or major cytogenetic response, i.e. a reduction to 0-34%
Ph-positive cells. This positive effect may be attained in
cases with a simple t(9;22), in such with complex translo-
cations resulting in a BCR/ABL fusion gene, as well as in
cases with cytogenetic clonal evolution [5,6].
Herein we report a rare case of a Ph chromosome
positive CML with a derivative chromosome 16 leading
to a partial trisomy 17q21 to 17qter and partial deletion
of 16pter, which was nonetheless successfully treatable
by Imatinib.
* Correspondence: scientific@aec.org.sy
1Molecular Biology and Biotechnology Department, Human Genetics
Division, Atomic Energy Commission, Damascus, Syria
Al Achkar et al. Molecular Cytogenetics 2010, 3:6
http://www.molecularcytogenetics.org/content/3/1/6
© 2010 Al Achkar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Case report
A 30-year old male was diagnosed to suffer from CML in
CP after a blood cell count was initiated in June 2009 due
to splenomegaly and severe loss of weight. The patient
was treated with Imatinib mesylate at a 400 mg/day for
overall 12 months and previous relevant symptoms
disappeared. Hematologic parameters were as follows:
hemoglobin 129 g/l; platelets count was 103 × 10
9/l; and
white blood cells (WBC), 5 × 10
9/l with 57.2% neutro-
phils, 36.3% lymphocytes, 4.8% monocytes, 1.3% eosino-
philes and 0.4% basophiles.
Karyotyping was done after initiation of chemotherapy
treatment, showing the following karyotypic changes. A
complex karyotype 48,XY,+8,t(9;22)(q34;q11),der(16),
t(16;17),+der(22)/47,XY,+8,t(9;22)(q34;q11),der(16),
t(16;17)/46,XY,t(9;22)(q34;q11) was determined in GTG-
banding (Fig. 1) and further specified by molecular cyto-
genetic studies (Fig. 2, 3). Dual-color-FISH using a
probe specific for BCR and ABL revealed a typical Phila-
delphia-chromosome with BCR/ABL fusion gene was
present and the second derivative chromosome 22 was a
second Ph chromosome (Fig. 2). M-FISH, was applied
to exclude further cryptic rearrangements (Fig. 3A). As
no other additional changes were found by that
approach, array-proven high-resolution multicolor band-
ing (aMCB) (10) probe sets for chromosomes 16 and 17
were applied. Thus, an intrachromosomal rearrangement
on the derivative chromosome 16 was detected addition-
ally to the translocation of chromosome 17 material to
the derivative chromosome 16 (Figs. 3B and 3C). Finally,
a subtelomeric probe for 16pter revealed a partial dele-
tion on the derivative chromosome 16 (Fig. 3D). Thus,







In a case of a CP Ph chromosome positive CML addi-
tional chromosomal changes were detected. Apart from
a trisomy 8 and an additional derivative chromosome 22
two additional chromosomal alterations were present:
an intrachromosomal rearrangement involving 16q22,
16p11.3 and an interchromosomal one with breakpoints
in 16q22 and 17q21. To our knowledge, this transloca-
tion has been never observed in CML before [7].
In 5-10% Ph chromosome CML cases have complex
translocations in addition to those and/or besides chro-
mosomes 9 and 22 [1]. At present it appears that in such
rearrangements any other chromosome may be involved.
However, it has been suggested that distribution of chro-
mosomes and breakpoints is non-random with the chro-
mosomal bands most susceptible to breakage being 1p36,
3p21, 5q31, 6p21, 9q22, 10q22, 11q13, 12p13, 17p13,
17q21, 17q25, 19q13, 21q22, 22q12 and 22q13 [8], show-
ing one match with the present case, i.e. 17q21.
Additionally, the two breakpoints in chromosome 16
have previously been reported to be associated with acute
nonlymphocytic leukemia (ANLL) type M4 [9]. 16q22
is frequently found in the ANLL typical inversion (16)
(p13q22) and the related interchromosomal translocation
(16;16)(p13;q22). These chromosome 16 rearrangements
resulted in the disruption of the myosin heavy chain
(MYH11) gene mapping to chromosome 16p13.13
to 16p13.12 [10]. MYH11 encodes the smooth-muscle
Figure 1 GTG-banding revealed a complex karyotype involving
two further chromosomes besides chromosomes 9 and 22. All
derivative chromosomes are marked by arrowheads. Karyotype: 48,
XY,+8,t(9;22)(q34;q11),der(16),t(16;17),+der(22).
Figure 2 Fluorescence in situ hybridization (FISH) using probes
for BCR (green) and ABL (red) showed the presence of two Ph-
chromosomes. Abbreviations: # = chromosome; der = derivative
chromosome; Ph = Philadelphia-chromosome.
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tional myosins. The well-characterized biological function
of myosins is their ability to use the energy of ATP hydro-
lysis to move actin filaments and produce muscle force.
Recently, myosins have been implicated in a variety of
other intra-cellular functions, including cell migration,
adhesion, control of cell shape, and membrane traffic but
are implicated also in a variety of other cellular functions,
many of which are relevant for cancer formation [11].
Unfortunately, in the present case no material was avail-
able to test if MYH11 was involved in the rearrangement.
During CML progression trisomy of chromosomes
8 and a second Ph chromosome are frequent anomalies
in CML [3]. Also, another leukemogenic effect of the
der(16) may be due to increase copy number of the
17q21 to 17qter region. Morerio et al. [12] have
reported that trisomies for this region represent a nega-
tive prognostic indicator in myeloid neoplasia. Also an
isochromosome 17q is a well-known progression step in
CML.
In conclusion, here we reported a novel and cytogen-
etically unique case of a Ph chromosome positive CML
in CP. Especially the latter fact being still a CML in CP
and not in BC when having such complex secondary
chromosomal aberrations is intriguing. We suggest that
the reported patient had nonetheless such a good
response to Imatinib as irrespective of complex
Figure 3 Karyotype and chromosomal aberrations were confirmed using molecular cytogenetic approaches. (A) M-FISH confirmed the
complexity of the karyotype: 47,XY,t(9;22),der(16)t(16;17),+8. (B) and (C) The application of MCB 16 and 17 revealed the chromosomal breakpoints
on the corresponding derivative chromosomes as 16p13.3 and 16 q22 and 17q21. (D) The deletion of the subtelomeric region on the der(16)
and the translocation of chromosome 17 material was also demonstrated by the application of a subtelomeric probe for 16p (Abbott Molecular/
Vysis, USA) and a whole chromosome painting (wcp) probe for chromosome 17.
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before further mutations appeared leading to BC.
Materials and methods
Chromosome analysis
Chromosome analysis using GTG-banding was done
according to standard procedures [13]. 20 metaphases
analyzed from unstimulated bone marrow culture were
analyzed. Karyotypes were described according to the
International System for Human Cytogenetic Nomencla-
ture [14].
Molecular cytogenetics
Fluorescence in situ hybridization (FISH) using LSI
BCR/ABL dual color dual fusion translocation probe
(Abbott molecular/Vysis, USA) and subtelomeric probe
for 16pter (Abbott molecular/Vysis, USA) were applied
according to manufacturer’s instructions together with a
whole chromosome painting (WCP) probe for chromo-
some 17 [15]. Array-proven multicolor banding probe
(aMCB) sets based on microdissection derived region-
specific libraries for chromosome 16 and 17 were
applied as described [16] 20 metaphase spreads were
analyzed, each using a fluorescence microscope (AxioI-
mager.Z1 mot, Zeiss) equipped with appropriate filter
sets to discriminate between a maximum of five fluoro-
chromes and the counterstain DAPI (Diaminophenylin-
dol). Image capturing and processing were carried out
using an ISIS imaging system (MetaSystems, Altlus-
sheim, Germany) for the evaluation aMCB.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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